News & Features -
-
Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in Israel
(Feb 01) More
-
Cerus Announces Contracts for 19 New INTERCEPT Blood System Illuminators in Russia
(Dec 06) More
-
Cerus Announces New Supply Agreement with French National Blood Service
(Nov 10) More
-
ISBT 2011 Taipei
(Nov 01) More
A Single Pathogen Inactivation System for Both Platelets and Plasma
The INTERCEPT Blood System™ is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It is the first system available to treat both platelets and plasma, and simplifies processing by utilizing the same illumination device, process and active compound. This synergistic approach is designed to meet blood center requirements for efficiency, performance and compatibility with both whole blood and apheresis collections. More |
|
|
|||||
|
INTERCEPT E-NEWSLETTER INTERCEPT eNews delivers product news & information updates right to your inbox. |
UNITED STATES RESIDENTS This site is intended for use by healthcare professionals outside of the United States only. If you are a resident of the United States, please see important information HERE. |
APPROVAL STATUS |
|
||


